Which emergency contraceptive methods are the most effective for preventing pregnancy after unprotected intercourse?

CONCLUSIONS
Levonorgestrel (which is as effective when used as a single dose of 1.5 mg or as 2 doses of 0.75 mg taken 12 h apart) and mifepristone, 25–50 mg, are effective emergency methods for preventing pregnancy after unprotected intercourse.

Commentary

The review by Cheng et al concludes that levonorgestrel or mifepristone are more effective and better tolerated than the traditionally used Yuzpe method. Mifepristone, however, remains controversial because of its identity as the “abortion” pill. It is also associated with delayed onset of menses. The thorough search of specialised databases, inclusion of studies in any language, consultation with experts, and sound methodological quality of most of the individual studies gives strength to the authors’ conclusions. A levonorgestrel regimen of 1.5 mg, as a single or divided dose, is the treatment of choice when available, although it may be more costly than the Yuzpe method.

The clinical safety and effectiveness of emergency contraception is well established. The challenge for clinicians is to promote the appropriate use of this underused contraceptive option. Few women report having ever used emergency contraception.1,2 It is likely that wider use could prevent many unwanted pregnancies and prevent abortions. Some countries are initiating changes that will make emergency contraception available through pharmacists without prescription. Over-the-counter sales will dramatically increase access and should be supported by healthcare professionals. Clinicians might also consider providing women or couples with an advance dose of emergency contraception for use after unprotected intercourse. Although this approach is controversial, adolescents provided with an advance dose do not have more unprotected sex and actually increase their use of condoms or oral contraceptives.3

The take home message is that emergency contraception is safe and effective, and access to this important contraceptive option should be expanded.

Scott Gibson, RN-EC, BScN
Niagara Health System, Niagara-on-the-Lake Site
Niagara-on-the-Lake, Ontario, Canada


---

**Pregnancy rates for various emergency contraceptive methods after unprotected intercourse**

<table>
<thead>
<tr>
<th>Comparisons</th>
<th>Number of trials [n]</th>
<th>Weighted event rates</th>
<th>RRR (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intrauterine device vs expectant management</td>
<td>1 (300)</td>
<td>2% v 22%</td>
<td>91% (74 to 97)</td>
<td>5 (4 to 9)</td>
</tr>
<tr>
<td>Levonorgestrel vs the Yuzpe regimen</td>
<td>2 (2789)</td>
<td>1.3% v 3.3%</td>
<td>49% (17 to 69)</td>
<td>50 (34 to 101)</td>
</tr>
<tr>
<td>Mifepristone vs the Yuzpe regimen</td>
<td>3 (2144)</td>
<td>0.45% v 2.5%</td>
<td>86% (59 to 95)</td>
<td>50 (34 to 100)</td>
</tr>
<tr>
<td>Mifepristone, 25–50 mg v &lt;10 mg</td>
<td>10 (8762)</td>
<td>0.73% v 1.7%</td>
<td>38% (12 to 57)</td>
<td>100 (100 to 100)</td>
</tr>
<tr>
<td>Mifepristone v anodrin</td>
<td>3 (439)</td>
<td>0.09% v 4.1%</td>
<td>80% (8 to 96)</td>
<td>25 (15 to 100)</td>
</tr>
<tr>
<td>Mifepristone v danazol</td>
<td>2 (629)</td>
<td>0.47% v 4.5%</td>
<td>90% (45 to 98)</td>
<td>25 (15 to 50)</td>
</tr>
</tbody>
</table>

*Abbreviations defined in glossary; weighted event rates, RRR, NNT, and CI calculated from data in article using a fixed effects model.*
Review: levonorgestrel and mifepristone are effective emergency methods for preventing pregnancy after unprotected intercourse

*Evid Based Nurs* 2005 8: 15
doi: 10.1136/ebn.8.1.15

Updated information and services can be found at:
http://ebn.bmj.com/content/8/1/15

**References**
This article cites 2 articles, 0 of which you can access for free at:
http://ebn.bmj.com/content/8/1/15#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Reproductive medicine (335)
- Pregnancy (254)
- Contraception (45)
- Drugs: obstetrics and gynaecology (44)
- Internet (387)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/